Catalyst Calendar
Scope

Thu, Jul 9, 2026

1 updates
DNLI
4:01 PM

Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier

Denali co-founder and CEO Ryan Watts, Ph.D., to deliver opening plenary address at 2026 AAIC in London on July 12, 2026 Presentation will highlight recent scientific advances and future opportunities to accelerate discovery and development of medicines for neurodegenerative diseases Denali is

denalitherapeutics.com

Thu, Jun 18, 2026

1 updates

Thu, May 21, 2026

1 updates
DNLI
6:00 PM

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

The Phase 2b LUMA study of BIIB122 in early-stage Parkinson’s disease did not meet its primary or secondary endpoints Based on data from the Phase 2b LUMA study, Biogen and Denali will discontinue development of BIIB122 in idiopathic Parkinson’s disease Denali continues to independently conduct

Trial Results • Phase 2Results event Thu, May 21, 2026denalitherapeutics.com

Thu, May 7, 2026

1 updates